Cesare Gridelli

Brigatinib versus Crizotinib in <i>ALK</i> -Positive Non–Small-Cell Lung Cancer

D. Ross Camidge, Hye Ryun Kim, Myung‐Ju Ahn et al. · New England Journal of Medicine · 2018 · 945 citations · Full text

Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Solange Peters, Alex A. Adjei, Cesare Gridelli et al. · Annals of Oncology · 2012 · 927 citations · Full text

Advanced Lung Disease, Medicine, Cancer Management +5

Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial

Alice T. Shaw, Tae Min Kim, Lucio Crinò et al. · The Lancet Oncology · 2017 · 574 citations · Full text

Medicine, Ceritinib Versus Chemotherapy, Pathology +6

Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study

Armando Santoro, Lorenza Rimassa, Ivan Borbath et al. · The Lancet Oncology · 2012 · 549 citations

Second-line Treatment, Placebo-controlled Phase 2, Oncology +11

Symptomatic Toxicities Experienced During Anticancer Treatment: Agreement Between Patient and Physician Reporting in Three Randomized Trials

Massimo Di Maïo, Ciro Gallo, Natasha B. Leighl et al. · Journal of Clinical Oncology · 2015 · 478 citations · Full text